Clinical Laserthermia Systems (CLS-B.ST) Stock Analysis & AI Equity Report
Clinical Laserthermia Systems (CLS-B.ST) overview
Clinical Laserthermia Systems (CLS-B.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Clinical Laserthermia Systems reported revenue of SEK 17.5m and operating profit of SEK -29.0m; the year-end share price was 6.88 SEK and market capitalisation was SEK 178m. Clinical Laserthermia Systems is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Clinical Laserthermia Systems's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-05-11. Data will be refreshed during report generation.
About Clinical Laserthermia Systems
Clinical Laserthermia Systems develops and sells TRANBERG thermal therapy systems for minimally invasive treatment of cancerous tumors and drug-resistant epilepsy. Its products include the Thermoguide Workstation, laser applicators, introducers, and sterile disposables used for image-guided laser ablation, along with temperature and treatment monitoring devices. The company is headquartered in Lund, Sweden.
Generate the Clinical Laserthermia Systems report
Clinical Laserthermia Systems is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Clinical Laserthermia Systems and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.